What Pharma Leaders Are Prioritizing This Year – Top Bets and Blind Spots

As 2026 begins, pharma leaders are placing sharper bets earlier while navigating increasing pressure across pricing, access, and evidence. In this episode, Matt Riordan, Group President, Putnam, shares a candid, executive-level view of what leaders are prioritizing this year, where confidence is high, and where blind spots may limit impact. Drawing on real-world leadership conversations, the discussion explores how access and evidence expectations are shifting upstream and what it takes to pressure-test assumptions, align strategy earlier, and lead with greater clarity in 2026.

Panel – Mindy McGrath, Matt Riordan  

Recording & Editing – Mike Liberto, Rachel Skonecki 

For additional discussion, please contact us at TrendingHealth.com.